Key result
Reduced serum BDNF is linked to higher MACE risk in CHD patients.
Why the study?
BDNF protects against cardiovascular inflammation and retards Th1 and Th17 differentiation, but its association with Th1/Th2, Th17/Treg ratios, and MACE in CHD was unclear.
Does serum BDNF correlate with inflammatory T cell ratios and MACE risk in patients with coronary heart disease?
Cohort (n=310)
Does serum BDNF correlate with inflammatory T cell ratios and MACE risk in patients with coronary heart disease?
p-value: p=0.006
Lower serum BDNF levels correlate with higher inflammatory T cell ratios and an increased risk of major adverse cardiovascular events in patients with coronary heart disease.
BDNF levels should not yet guide CHD management; leaves open incremental value for MACE prediction beyond standard factors.
Background Brain‐derived neurotrophic factor (BDNF) exerts protective roles against dyslipidemia, atherosclerosis, and inflammation in cardiovascular diseases; meanwhile, it retards CD4+ T cell differentiation into T helper (Th)1 and Th17 cells. Hence, this study aimed to investigate the linkage of serum BDNF with Th1/Th2 ratio, Th17/regulatory T (Treg) ratio, and major adverse cardiovascular events (MACE) risk in the coronary heart disease (CHD) patients. Methods This prospective study detected serum BDNF in 210 CHD patients, 50 disease controls (DCs), and 50 healthy controls (HCs) using an enzyme‐linked immunosorbent assay. For CHD patients only, the proportion of Th1, Th2, Th17, and Treg cells in blood CD4+ T cells was calculated by flow cytometry. Results The BDNF varied among CHD patients, DC, and HC (p < 0.001). Specifically, BDNF was declined in CHD patients compared with DCs (p < 0.001) and HCs (p < 0.001). In CHD patients, BDNF was negatively related to Th1 cells (p = 0.031), Th1/Th2 ratio (p = 0.026), Th17 cells (p = 0.001), and Th17/Treg ratio (p = 0.002). Concerning the prognosis, BDNF was reduced in patients with MACE occurrence compared to patients without MACE occurrence (p = 0.006). Furthermore, BDNF showed a trend (lacked statistical significance) to relate to longer MACE‐free survival (p = 0.059). Besides, BDNF was related to the absence of obesity (p = 0.019), decreased total cholesterol (p = 0.043), low‐density lipoprotein cholesterol (p = 0.019), C‐reactive protein (p = 0.012), and Gensini score (p = 0.005). Conclusion Serum BDNF negatively correlates with Th1/Th2 ratio, Th17/Treg ratio, and estimates lower MACE risk in CHD patients.
No takes yet. Share an insight, caveat, or question.
Huo et al. (2022) conducted a cohort in Coronary heart disease (n=310). Serum brain-derived neurotrophic factor (BDNF) vs. Disease controls and healthy controls was evaluated on Major adverse cardiovascular events (MACE) occurrence (p=0.006). Serum BDNF was significantly lower in CHD patients versus controls (P<0.001) and reduced levels were associated with MACE occurrence (P=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: